Max Chat
Share chart Generation Bio Co.
Extended chart
Simple chart
About Generation Bio Co.
Generation Bio Co., компания по производству генетических лекарств, разрабатывает генную терапию для лечения редких и распространенных заболеваний. Компания разрабатывает портфель из восьми программ для лечения редких и распространенных заболеваний печени и сетчатки. Она также фокусируется на заболеваниях скелетных мышц, центральной нервной системы и онкологии. Компания ранее была известна как Torus Therapeutics, Inc. и сменила свое название на Generation Bio Co. в ноябре 2017 года. Generation Bio Co. была основана в 2016 году со штаб-квартирой в Кембридже, штат Массачусетс.Main settings
IPO date
2020-06-12
ISIN
US37148K1007
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 3.55 | 5 |
| P/BV | 0.8192 | 9 |
| P/E | 151.29 | 1 |
Efficiency
| Title | Value | Grade |
| ROA | -43.46 | 0 |
| ROE | -91.02 | 0 |
| ROIC | -27.33 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -1.26 | 10 |
| Debt/Ratio | 0.4047 | 10 |
| Debt/Equity | 1.68 | 7 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 55155.56 | 10 |
| Yield Ebitda, % | -8.43 | 0 |
| Yield EPS, % | -29.67 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 0.383 $ | 0 $ | 0 $ | -0 % | 0 % | 0 % |
| Week | 0.436 $ | 0 $ | 0 $ | -12.16 % | 0 % | 0 % |
| Month | 0.3799 $ | 0.383 $ | 0.383 $ | +0.816 % | 0 % | 0 % |
| Three month | 0.3725 $ | 0.3469 $ | 0.4504 $ | +2.82 % | 0 % | 0 % |
| Half a year | 0.7806 $ | 0.324 $ | 0.9899 $ | -50.94 % | 0 % | 0 % |
| Year | 2.64 $ | 0.324 $ | 3.51 $ | -85.49 % | 0 % | 0 % |
| 3 years | 5.11 $ | 0.324 $ | 8.34 $ | -92.5 % | 0 % | 0 % |
| 5 years | 24.37 $ | 0.324 $ | 51.61 $ | -98.43 % | 0 % | 0 % |
| 10 years | 0.324 $ | 0.324 $ | 51.61 $ | +118.21 % | 0 % | 0 % |
| Year to date | 0.9375 $ | 0.324 $ | 1.15 $ | -59.15 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| Atlas Venture Life Science Advisors, LLC | 8 279 484 | 12.45 |
| Price (T.Rowe) Associates Inc | 6 926 174 | 10.42 |
| FMR, LLC | 5 352 399 | 8.05 |
| Bellevue Group AG | 3 617 080 | 5.44 |
| Blackrock Inc. | 3 168 415 | 4.77 |
| Artal Group S.A. | 2 814 191 | 4.23 |
| Vanguard Group Inc | 2 552 251 | 3.84 |
| Bank of America Corporation | 2 527 862 | 3.8 |
| EcoR1 Capital, LLC | 2 046 867 | 3.08 |
| PFM Health Sciences, LP | 1 622 487 | 2.44 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Dr. Matthew Norkunas M.B.A., M.D. | Chief Financial Officer | 611.11k | 1978 (47 years) |
| Dr. Robert Kotin Ph.D. | Co-Founder | N/A | 1956 (69 years) |
| Dr. Matthew Stanton Ph.D. | Chief Scientific Officer | 654.83k | 1973 (52 years) |
| Dr. Mark D. Angelino Ph.D. | Co-Founder | N/A | 1973 (52 years) |
| Dr. Cameron Geoffrey McDonough M.D. | President, CEO & Director | 939.09k | 1970 (55 years) |
| Ms. Jasmin Tower | Chief Human Resources Officer | N/A | |
| Ms. Antoinette Paone M.B.A., M.S. | Chief Operating Officer | N/A | 1978 (47 years) |
| Ms. Yalonda Howze J.D. | Chief Legal Officer & Secretary | N/A | 1972 (53 years) |
| Dr. Phillip Samayoa Ph.D. | Chief Strategy Officer | N/A | 1987 (38 years) |
About company
Address: United States, Cambridge, 301 Binney Street - Open in google maps, Open in yandex maps
Website: http://generationbio.com
Website: http://generationbio.com
